Extensively Drug-Resistant Tuberculosis

This is a very serious type of tuberculosis. It means the TB bacteria are resistant to the strongest first-line drugs used to treat TB. It also means they are resistant to many other important second-line drugs. This makes the TB very hard to treat and can be life-threatening. Doctors need to use special, stronger drugs to try and cure it.

Condition

What people with Extensively Drug-Resistant Tuberculosis report

Every report comes from a Lived member, sent anonymously.

Have you tried Zyvox (Linezolid) for Extensively Drug-Resistant Tuberculosis?

NameHow it went

About Extensively Drug-Resistant Tuberculosis

What It Is

Extensively drug-resistant tuberculosis (XDR-TB) is tuberculosis caused by bacteria that the most important TB medicines can no longer kill. Ordinary TB is a bacterial infection, usually of the lungs, that is cured with a few months of standard antibiotics. In XDR-TB, the bacteria resist isoniazid and rifampin, the two main first-line drugs, and also a fluoroquinolone (an antibiotic family that includes levofloxacin and moxifloxacin), plus at least one more key drug such as bedaquiline or linezolid. US case reporting also counts TB that resists an older injectable antibiotic, such as amikacin, in place of bedaquiline or linezolid. The illness itself looks like other TB: a lasting cough, sometimes with blood, along with fever, night sweats, weight loss and tiredness. The difference lies in treatment. Because so few medicines still work, XDR-TB carries a higher risk of severe illness and death than TB that responds to standard drugs. It is rare in the United States, where a single case was reported in 2023, and is more often seen in countries where drug-resistant TB is common. The definition changed in 2021, so older articles and statistics may use the term for a group that today would mostly be called pre-XDR-TB: resistance to isoniazid, rifampin and a fluoroquinolone, but not to bedaquiline or linezolid.

Causes & Risk Factors

Resistance develops when TB bacteria are exposed to medicines that do not fully kill them. This can happen when a treatment course is interrupted, doses are missed, the regimen is not right for the strain, or drug supplies run out. The bacteria that survive are the ones able to resist those drugs. Over time, and especially after more than one incomplete course, resistance can build to the point of XDR-TB. Responsibility for avoiding this rests largely with the treatment program, which is why TB care includes close support for taking every dose. People can also catch XDR-TB directly. It spreads through the air in the same way as ordinary TB, when someone with active disease in the lungs or throat coughs, sneezes, talks or sings. A person infected this way has resistant TB even if they have never taken TB medicine. Spending time with someone who has drug-resistant TB, coming from or living in an area where it is common, and a past TB treatment that was not completed all raise the chance that a case is drug-resistant. HIV (human immunodeficiency virus) and other conditions that weaken the immune system make it more likely that an infection becomes active disease.

How It's Diagnosed

Diagnosing XDR-TB has two parts: confirming active TB, then finding out which medicines the bacteria resist. TB disease in the lungs is usually confirmed by testing sputum (mucus coughed up from the lungs) and by a chest X-ray. Skin and blood tests show only that someone has been infected with TB at some point, so they cannot diagnose drug resistance. Resistance can be confirmed only by drug-susceptibility testing, which checks the person's own bacteria against each medicine. Molecular tests look for genetic changes known to cause resistance and can return results within a day or two, which lets doctors avoid starting a regimen that will not work. Growing the bacteria in culture and testing them against each drug takes longer, often several weeks or more, but covers more medicines. In the United States, public health laboratories and the Centers for Disease Control and Prevention offer these specialized tests. Testing is repeated if cultures still grow TB after about three months of treatment or if the person is not improving, since resistance can increase during treatment.

Treatment Options

XDR-TB can often be cured, but treatment is demanding and should be directed by a team experienced in drug-resistant TB, usually alongside the local health department. The plan depends on exactly which drugs the bacteria resist and which medicines the person has already taken. A six-month all-oral regimen called BPaL is a major option when the bacteria still respond to bedaquiline and linezolid. That applies to XDR-TB counted under the older injectable-based rule and to pre-XDR TB, not to TB already resistant to bedaquiline or linezolid. BPaL is used for TB in the lungs in people 14 and older who have not already taken bedaquiline or linezolid for more than about a month. It combines bedaquiline (Sirturo), a newer TB antibiotic; pretomanid, a TB antibiotic approved only for use in this combination; and linezolid, an antibiotic also used for other serious infections. In the study that led to its approval, about 9 in 10 people with highly drug-resistant TB had a good outcome six months after finishing treatment. That study had no comparison group, and many of its participants would be classified as pre-XDR today. Doses are usually taken with food and watched by a health worker, an arrangement called directly observed therapy that helps make sure no doses are missed. When the bacteria resist bedaquiline or linezolid, as in XDR-TB under the current definition, specialists build an individual regimen from the remaining drugs that testing shows still work, which often means more medicines and a longer course, commonly well over a year. Evidence for these regimens is limited, and results are less predictable. Surgery to remove a badly damaged part of a lung is sometimes added for people whose infection is unlikely to clear with medicine alone. Side effects are a real part of treatment. Linezolid often causes numbness or tingling in the hands and feet and can lower blood counts or affect vision, so it is frequently reduced or paused. Bedaquiline can change heart rhythm, and the combination can stress the liver, so treatment includes regular blood tests, heart tracings (electrocardiograms, or ECGs) and vision checks.

What to Expect

Treatment for XDR-TB takes months at minimum and can take more than a year. In the first weeks, people with TB in the lungs are usually asked to stay home or in a hospital and limit close contact with others until treatment has made them non-infectious, a decision made with the health department. Feeling better is not the measure of success. Sputum tests are repeated until the bacteria stop growing, and the full course must be finished even after symptoms fade, because stopping early can let the most resistant bacteria return. Daily life often revolves around the treatment schedule: observed doses, frequent monitoring visits and managing side effects. Time away from work, the strain of isolation and the cost of travel can be substantial, so it helps to raise practical obstacles with the care team early. People close to the person, especially household members, young children and anyone with HIV, are usually checked by the health department for infection. After treatment ends, follow-up continues for a period to make sure the infection has not come back.

When to Seek Help

Ask for TB testing if you have a cough lasting more than three weeks, cough up blood, or have fevers, night sweats or unexplained weight loss, particularly after time with someone who has drug-resistant TB or after earlier TB treatment that was not finished. During treatment, contact your TB care team promptly about blurred or changing vision, yellowing of the skin or eyes, dark urine, or persistent nausea and loss of appetite. Also tell them about new or worsening numbness, tingling or burning in the hands or feet, fainting or a racing or irregular heartbeat, or anything that makes it hard to keep taking every dose, so the plan can be adjusted rather than interrupted.

Questions to Ask Your Doctor

  1. 1.Which drugs do my bacteria resist, and what does that mean for which treatment I can have?
  2. 2.Am I a candidate for the six-month BPaL regimen, or will I need a longer individual regimen?
  3. 3.How will we watch for side effects such as nerve, vision, blood count or heart rhythm changes, and what happens if they appear?
  4. 4.How long will I need to stay away from others, and who among my family and contacts should be tested?
  5. 5.What support is available to help me complete treatment, such as help with travel, time off work or how doses are observed?

Last reviewed • Oct 2026

Educational content, not medical advice.